Investigated for use/treatment in bacterial infection, skin infections/disorders, obesity, liver disease, kidney disease, and pneumonia.
- Mechanism
- Curator reviewed
Iclaprim is a novel diaminopyrimidine, and an inhibitor of dihydrofolate reductase, which has shown potent, extended-spectrum in vitro activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus, vancomycin-intermediate and vancomycin-resistant S. aureus and macrolide-, quinolone- and trimethoprim-resistant strains. In addition, iclaprim has demonstrated activity against Streptococcus pneumoniae including penicillin-, erythromycin-, levofloxacin- and trimethoprim/sulfamethoxazole-resistant strains.
- Primary indication
- Investigated for use/treatment in bacterial infection, skin infections/disorders, obesity, liver disease, kidney disease, and pneumonia.Curator reviewed
- Formula / weight
- C19H22N4O3 · 354.41 g/mol (avg)
- Code names
- AR-100 · AR-100.001 · RO 48-2622
Resolves to
HWJPWWYTGBZDEG-UHFFFAOYSA-NSMILESCOC1=CC(CC2=CN=C(N)N=C2N)=C2C=CC(OC2=C1OC)C1CC1What you can answer from here — as of August 30, 2026
Which drugs share a target with Iclaprim, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account